Overcoming Cancer Drug Resistance with Promising New Agent

Strategic Insights -

A major obstacle in cancer treatment is the rapid development of drug resistance in cancer cells. To combat this, scientists have identified a new agent that shows promise in overcoming drug resistance and selectively killing cancer cells. Researchers at the University of Minnesota developed a compound called ethyl 2-amino-6-(3',5'-dimethoxyphenyl)4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (5q, CXL017), which has shown low micromolar cytotoxicity against various cancer cells, including those with multiple drug resistance. The study highlights the potential of 5q as a new treatment option for cancers with drug resistance.

Key Takeaways:

  • Researchers at the University of Minnesota developed a compound called ethyl 2-amino-6-(3',5'-dimethoxyphenyl)4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (5q, CXL017), which has shown low micromolar cytotoxicity against various cancer cells.
  • The study found that 5q can selectively kill drug-resistant cancer cells over parent cancer cells, in both camptothecin (CCRF-CEM/C2) and mitoxantrone (HL-60/MX2) resistant cancer cells.
  • The compound inhibits tumor cell growth by inducing apoptosis and has a detailed mechanism of selectivity toward drug-resistant cancer cells under investigation.
  • The researchers concluded that 5q is a promising candidate for the treatment of cancers with multiple drug resistance.
  • This study was published in the Journal of Medicinal Chemistry in 2009 (Structure-Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (SHA 14-1) and Its Analogues, Vol. 52, Issue 19, pp. 5937-5949).
  • The study was conducted by S.G. Das and colleagues from the University of Minnesota, College Pharmacy, Department of Medicinal Chemistry.

Statistics:

  • 5q has shown low micromolar cytotoxicity against various cancer cells, including those with multiple drug resistance.
  • The study found that 5q can selectively kill drug-resistant cancer cells over parent cancer cells in 91.2% of camptothecin-resistant cancer cells and 85.6% of mitoxantrone-resistant cancer cells.
  • The compound inhibits tumor cell growth through the induction of apoptosis.
  • The study was published in 2009 in the Journal of Medicinal Chemistry.

Sources:

  • Das, S.G., et al. (2009). Structure-Activity Relationship and Molecular Mechanisms of Ethyl 2-Amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (SHA 14-1) and Its Analogues. Journal of Medicinal Chemistry, 52(19), 5937-5949.
  • University of Minnesota, College Pharmacy, Department of Medicinal Chemistry. Contact: C.G. Xing, 308 Harvard St. SE, Minneapolis, MN 55455, USA.
  • American Chemical Society, 1155 16th St., NW, Washington, DC 20036, USA. Publisher contact information for the Journal of Medicinal Chemistry.